Feline Hyperthyroidism

Overview

Feline hyperthyroidism is a common endocrine disorder of older cats caused by excessive production of thyroid hormones from abnormal thyroid tissue. Most affected cats have benign nodular hyperplasia or adenoma; malignant thyroid carcinoma is much less common. The disease increases metabolic demand and can affect the cardiovascular, gastrointestinal, renal, muscular and nervous systems.

Management requires more than confirming an increased total thyroxine concentration. The clinician must consider the cat’s clinical status, blood pressure, cardiac findings, renal reserve, temperament, household circumstances and the owner’s ability to administer treatment and attend monitoring. Several effective treatments are available, but they differ in whether they control or cure the disease and in their practical implications.

Clinical significance

Untreated hyperthyroidism is progressive. Persistent thyrotoxicosis can contribute to weight loss, muscle wasting, tachycardia, hypertension, gastrointestinal signs and cardiac remodelling. Increased renal blood flow and glomerular filtration may mask underlying chronic kidney disease. When euthyroidism is restored, renal dysfunction may become apparent, making staged assessment and monitoring particularly important.

Early recognition can be difficult because some cats remain active and maintain appetite while losing weight. Routine senior-cat assessment, including accurate weight and muscle-condition trends, can identify disease before severe deterioration occurs.

Aetiology and risk factors

The precise cause of the high prevalence of feline hyperthyroidism remains incompletely defined. Age is the clearest risk factor, and most affected cats are middle-aged to older. Environmental, nutritional and genetic influences have been investigated, but no single preventable cause explains all cases.

Functional thyroid tissue may be unilateral, bilateral or ectopic. Palpation of a cervical thyroid nodule supports suspicion but does not establish thyroid function, and a non-palpable gland does not exclude disease. Scintigraphy is the most informative method for locating all hyperfunctional tissue when available.

Clinical presentation

Common findings include weight loss despite normal or increased appetite, hyperactivity, restlessness, increased vocalisation, polydipsia, polyuria, vomiting, diarrhoea, unkempt coat and reduced muscle mass. Tachycardia, a gallop rhythm, murmur, bounding pulses and systemic hypertension may occur. Some cats present with lethargy, weakness or reduced appetite rather than the classic hyperactive phenotype.

History should address appetite, drinking, urination, gastrointestinal signs, activity, medication, diet, weight trajectory and ability to administer tablets or topical treatment. Examination should include body weight, body condition, muscle condition, heart rate and rhythm, thyroid palpation, retinal assessment where indicated and blood-pressure measurement using a calm, standardised technique.

Diagnostic approach

Diagnosis is based on compatible clinical findings and thyroid testing. An increased serum total thyroxine concentration in a cat with typical signs is usually diagnostic. A result within the reference interval does not always exclude early or fluctuating disease, particularly when the value is in the upper part of the interval. Repeating total thyroxine after an appropriate interval, reviewing concurrent illness and considering free thyroxine or thyroid imaging may be useful in equivocal cases.

Free thyroxine can increase sensitivity but may be elevated in cats without hyperthyroidism, so it should not be interpreted in isolation. Baseline evaluation commonly includes haematology, serum biochemistry, urinalysis, blood pressure and assessment for concurrent disease. Cardiac imaging may be appropriate when findings suggest clinically important heart disease. Thyroid scintigraphy can confirm disease, identify ectopic tissue and guide definitive treatment.

Differential diagnoses

Weight loss in an older cat has a broad differential list, including chronic kidney disease, diabetes mellitus, gastrointestinal disease, neoplasia, dental disease, chronic infection and inadequate intake or absorption. Tachycardia and hypertension may have other causes. Concurrent disease is common, so confirmation of hyperthyroidism should not end the diagnostic assessment when findings remain unexplained.

Treatment and management

Options include radioactive iodine, surgical thyroidectomy, medical treatment with an antithyroid drug and a restricted-iodine diet. Choice should be individualised. Radioactive iodine is a definitive treatment for most cats and can treat ectopic or bilateral tissue, but requires access to an authorised facility and a period of regulated hospitalisation. Surgery may be curative but depends on localisation, surgical expertise and perioperative risk; complications can include hypocalcaemia and damage to adjacent structures.

Medical treatment inhibits thyroid hormone synthesis and is reversible, making it useful for long-term control or as a trial before definitive treatment. It requires reliable administration and monitoring for adverse effects and effectiveness. A restricted-iodine diet can control thyroid hormone production when fed exclusively; even small amounts of other food may compromise efficacy, and suitability must be considered in multi-cat households and cats with competing nutritional needs.

Before definitive treatment, some clinicians use reversible therapy to evaluate how restoration of euthyroidism affects renal function. This does not predict every outcome, but it can assist decision-making. Treatment should aim for euthyroidism without causing hypothyroidism, while preserving renal function and quality of life.

Client communication and treatment selection

Treatment choice is best made through a structured discussion rather than presenting one option as universally preferable. Explain whether the proposed treatment controls hormone production or removes abnormal tissue, the expected monitoring burden, the possibility of hypothyroidism, the effect of concurrent kidney disease and any restrictions associated with hospitalisation or diet. Cost comparisons should consider the full course of care, including repeat testing, medication, travel and the likelihood of long-term administration.

Practical details often determine success. Tablet administration may be straightforward in one cat and impossible in another. Transdermal formulations can improve feasibility but still require consistent technique and monitoring. A therapeutic diet must be the sole food source, which may be difficult in outdoor cats or multi-cat households. Written instructions, a clear recheck timetable and guidance on warning signs reduce misunderstanding and help owners distinguish expected improvement from adverse effects or emerging concurrent disease.

Monitoring and follow-up

Monitoring intervals depend on the treatment selected and the cat’s stability. Early reassessment after starting or changing medical therapy typically includes clinical response, body weight, thyroid hormone concentration, renal values and adverse-effect screening. Blood pressure and cardiac status may also need review. Once stable, periodic monitoring remains necessary because dose requirements, renal function and concurrent disease can change.

After radioactive iodine or surgery, assess for persistent or recurrent hyperthyroidism and for hypothyroidism. Iatrogenic hypothyroidism may have important renal consequences and should not be dismissed as a laboratory curiosity. Owners should be asked about appetite, activity, vomiting, stool quality, drinking, urination, weight and ability to administer treatment.

Prognosis

Prognosis is often good when disease is controlled and important comorbidities are identified. Definitive treatment can provide long-term cure in many cats. Outcome is influenced by renal disease, cardiovascular disease, severity and duration of thyrotoxicosis, treatment tolerance and the presence of thyroid carcinoma.

Quality of life can improve substantially as weight, muscle condition, behaviour and gastrointestinal signs normalise. However, apparent clinical improvement does not remove the need for biochemical monitoring.

Prevention

No proven prevention strategy is available for most cats. Regular senior health assessment, longitudinal weight and muscle-condition tracking, blood-pressure measurement and appropriately selected laboratory testing support earlier detection. Owners should be encouraged to report unexplained weight loss or behavioural change promptly.

Key clinical points

• Interpret thyroid tests alongside clinical findings and concurrent illness.
• A normal total thyroxine result does not always exclude early disease.
• Assess renal function before and after restoration of euthyroidism.
• Discuss curative and controlling treatment options clearly.
• Monitor for both persistent hyperthyroidism and treatment-induced hypothyroidism.

Related calculators

Relevant VetCalc tools may include feline body-condition and muscle-condition resources, resting-energy calculations, blood-pressure interpretation aids and quality-of-life instruments. They support structured follow-up but do not replace thyroid testing and clinical review.

References

1. Carney HC, Ward CR, Bailey SJ, et al. 2016 AAFP Guidelines for the Management of Feline Hyperthyroidism.
2. Feline Veterinary Medical Association practice guidelines and consensus statements.
3. International Renal Interest Society educational guidance for chronic kidney disease.
4. Peer-reviewed reviews of feline hyperthyroidism epidemiology, diagnosis and treatment.

Editorial status: Guideline-informed draft requiring veterinary editorial review before publication. Drug selection and monitoring must follow current product information and local regulation.